Use of Glucagon-like Peptide-1 Receptor Agonists and Risk of Lymphedema After Breast Cancer Surgery

Glucagon-like peptide-1 receptor agonist exposure may be associated with a lower incidence of postmastectomy lymphedema in breast cancer patients.

• Postmastectomy lymphedema is a chronic complication that can occur after breast cancer treatment, especially following axillary surgery.
• Obesity and metabolic inflammation are recognized factors that may increase the risk of developing lymphedema.
• The study specifically focused on breast cancer patients who underwent mastectomy and/or axillary procedures.
• Findings suggest a potential link between glucagon-like peptide-1 receptor agonist exposure and reduced lymphedema incidence.

Simplified